KR102449530B1 - Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. - Google Patents
Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. Download PDFInfo
- Publication number
- KR102449530B1 KR102449530B1 KR1020160176561A KR20160176561A KR102449530B1 KR 102449530 B1 KR102449530 B1 KR 102449530B1 KR 1020160176561 A KR1020160176561 A KR 1020160176561A KR 20160176561 A KR20160176561 A KR 20160176561A KR 102449530 B1 KR102449530 B1 KR 102449530B1
- Authority
- KR
- South Korea
- Prior art keywords
- ephedra
- complex extract
- obesity
- baekchul
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000003579 anti-obesity Effects 0.000 title claims description 21
- 244000236658 Paeonia lactiflora Species 0.000 title description 7
- 235000008598 Paeonia lactiflora Nutrition 0.000 title description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 title description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title description 3
- 235000021511 Cinnamomum cassia Nutrition 0.000 title description 3
- 241001465251 Ephedra sinica Species 0.000 title description 3
- 241001474977 Palla Species 0.000 title description 3
- 241000092665 Atractylodes macrocephala Species 0.000 title description 2
- 244000046146 Pueraria lobata Species 0.000 title description 2
- 235000010575 Pueraria lobata Nutrition 0.000 title description 2
- 241000218671 Ephedra Species 0.000 claims abstract description 43
- 241000287828 Gallus gallus Species 0.000 claims abstract description 43
- 230000036541 health Effects 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 230000026731 phosphorylation Effects 0.000 claims abstract description 12
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims abstract 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims abstract 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 21
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 claims description 10
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 claims description 5
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 238000005265 energy consumption Methods 0.000 abstract description 20
- 235000020824 obesity Nutrition 0.000 abstract description 14
- 208000008589 Obesity Diseases 0.000 abstract description 13
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 230000037149 energy metabolism Effects 0.000 abstract description 8
- 210000002027 skeletal muscle Anatomy 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 5
- 241000736199 Paeonia Species 0.000 abstract description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 208000030159 metabolic disease Diseases 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 3
- 210000003470 mitochondria Anatomy 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000003098 myoblast Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000237502 Ostreidae Species 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000020636 oyster Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- -1 etc. Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 241001126925 Lobata Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y10S514/909—
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합추출물을 유효성분으로 함유하는 신체 에너지 소비 촉진을 통한 비만 억제 작용을 하는 조성물에 관한 것이다. 본 발명에 따른 상기 복합추출물은, 골격근 내 미토콘드리아에서 PGC1-α의 발현을 증가시키고, AMPK의 인산화를 촉진함으로써, 에너지대사를 촉진하는 효과가 탁월하다는 것이 확인된 바, 비만과 제2형 당뇨병 및 각종 대사성 질환의 치료, 예방, 또는 개선에 유용한 의약품 및 건강기능식품으로 활용될 수 있다.The present invention relates to a composition containing a complex extract of broiler chicken, baekchul, galgeun, peony and ephedra as active ingredients, which suppresses obesity by promoting body energy consumption. It was confirmed that the complex extract according to the present invention has an excellent effect in promoting energy metabolism by increasing the expression of PGC1-α in mitochondria in skeletal muscle and promoting phosphorylation of AMPK. It can be utilized as pharmaceuticals and health functional foods useful for the treatment, prevention, or improvement of various metabolic diseases.
Description
본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합추출물을 유효성분으로 함유하는 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 조성물에 관한 것이다.The present invention relates to a composition containing a complex extract of broiler chicken, baekchul, galgeun, peony and ephedra as active ingredients, which has anti-obesity effect through promoting body energy consumption.
비만치료는 크게 에너지의 흡수(energy intake)를 억제하거나 에너지의 소비(energy expenditure)를 증가시키는 2가지 방법으로 나눌 수 있다. 그러나 에너지의 흡수를 억제하기 위한 식욕 억제제는 중추신경계에 작용하여 향정신성 부작용을 일으킬 수 있다. 또한, 식욕억제제 복용을 통한 장기간의 식이제한 시 인체 항상성 조절 기전에 따라 기초대사율이 저하되어 체중감량 효과가 점차 줄어든다는 문제점이 있다. 따라서 보다 효율적이며 안정적인 비만 치료를 위해서는 에너지의 소비 증가를 통한 항비만 작용의 약물 개발이 필요하다.Obesity treatment can be largely divided into two methods: suppressing energy intake or increasing energy expenditure. However, appetite suppressants to suppress energy absorption may act on the central nervous system and cause psychotropic side effects. In addition, there is a problem in that the basal metabolic rate is lowered according to the body homeostasis regulation mechanism during long-term dietary restriction through taking an appetite suppressant, so that the weight loss effect is gradually reduced. Therefore, for a more efficient and stable treatment of obesity, it is necessary to develop an anti-obesity drug through increased energy consumption.
골격근(Skeletal muscle)은 미토콘드리아가 가장 풍부한 조직으로 에너지의 소비를 증가시키기 위한 중요한 표적기관이다. 미토콘드리아의 가장 중요한 기능은 체내 에너지 대사에서 역할을 수행하는 것이며 당과 지방산의 산화에 관여한다. 그러므로 골격근에서 미토콘드리아의 기능 저하는 비만 및 제2형 당뇨병 (Type 2 Diabetes Mellitus) 등과 같은 만성 대사성 질환이나 노화 관련 질환에 영향을 미친다. Skeletal muscle is a tissue rich in mitochondria and is an important target organ for increasing energy consumption. The most important function of mitochondria is to play a role in energy metabolism in the body and is involved in the oxidation of sugars and fatty acids. Therefore, the decrease in mitochondrial function in skeletal muscle affects chronic metabolic diseases such as obesity and type 2 diabetes mellitus or age-related diseases.
과산화소체 증식제-활성화 수용체 감마 보조인자-1 알파 (peroxisome proliferator-activated receptor gamma coactivator-1 alpha, PGC-1α)는 갈색지방, 간과 근육조직에서 세포 내 에너지 대사를 조절하는 것으로 알려져 있다 (Finck BN and Kelly DP, 2006). 골격근 내에서 PGC-1α는 세포 에너지 대사의 핵심 인자로 지방산 산화를 조절하고, 미토콘드리아 생합성을 증가시키는 작용을 한다. Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) is known to regulate intracellular energy metabolism in brown fat, liver and muscle tissue (Finck BN) and Kelly DP, 2006). In skeletal muscle, PGC-1α is a key factor in cellular energy metabolism, regulating fatty acid oxidation and increasing mitochondrial biosynthesis.
아데노신 일인산-활성화 단백질 키나아제 (Adenosine monophosphate-activated protein kinase, AMPK)는 세포 내 에너지 항상성 유지에 관여하는 효소로 골격근 내에서 지방산의 산화와 당 흡수를 촉진하며, 근육 내 AMPK의 활성화는 PGC-1α 발현을 직접적으로 증가시킨다. Adenosine monophosphate-activated protein kinase (AMPK) is an enzyme involved in maintaining intracellular energy homeostasis. It promotes the oxidation of fatty acids and glucose uptake in skeletal muscle. directly increase expression.
한편, 육계 (Cinnamomum cassia Blume)는 한의학에서 당뇨병 및 비만 치료제로 활용하고 있는 약용 식물로, 약리작용은 대장균, 고초간균, 황색포도균, 폐렴쌍구균 등의 발육을 억제하고 유행성 감기바이러스를 억제하며 이뇨작용 등이 보고되었다.On the other hand, broiler chicken ( Cinnamomum cassia Blume) is a medicinal plant used as a treatment for diabetes and obesity in oriental medicine. action has been reported.
백출 (Atractylodes macrocephala Koidzumi)의 뿌리는 위장 질환, 복통, 비만의 치료를 위해 사용된다. 상기 백출 추출물이 항염증, 항궤양, 및 항종양 효과를 보이는 것도 확인되었다(C.-Q. Li, L.-C. He, and J.-Q. Jin, Phytotherapy Research, vol. 21, no. 4, pp. 347?353, 2007). Baekchul ( Atractylodes ) The root of macrocephala Koidzumi) is used for the treatment of gastrointestinal diseases, abdominal pain, and obesity. It was also confirmed that the baekchul extract exhibits anti-inflammatory, anti-ulcer, and anti-tumor effects (C.-Q. Li, L.-C. He, and J.-Q. Jin, Phytotherapy Research, vol. 21, no 4, pp. 347?353, 2007).
갈근 (Pueraria lobata (Willd.) Ohwi)은 근육을 풀어주면서 열을 내리는 기전으로 한의학에서 사용되는데 주요 화학성분은 이소플라본의 일종인 puerarin, daidzin 등이다. 암세포에 대한 일부의 연구에서 칡뿌리의 추출물 또는 분말을 처리했을 때 유방암 세포의 증식을 저해하고 유방암 종양의 성장이 감소되는 결과가 보고된 적이 있다. Garlic ( Pueraria ) lobata (Willd.) Ohwi) is used in oriental medicine as a mechanism to release heat while relaxing muscles. The main chemical components are puerarin and daidzin, which are isoflavones. In some studies on cancer cells, it has been reported that the treatment of arrowroot extract or powder inhibited the proliferation of breast cancer cells and reduced the growth of breast cancer tumors.
백작약 (Paeonia lactiflora Pallas)은 항염증 작용 및 스트레스성 궤양 예방효과가 보고되면서 이에 대한 다양한 연구가 진행되었다. 약리작용으로 중추신경계 억제, 평활근 이완 작용, 항혈소판 응집, 항염증, 항스트레스 및 항경련 효과, 항암효과, 식중독 유발 세균 증식 억제효과, 면역증강효과 등이 보고된 바 있다. Paeonia lactiflora Pallas has been reported to have anti-inflammatory and stress ulcer prevention effects, and various studies have been conducted on it. As pharmacological actions, central nervous system inhibition, smooth muscle relaxation, anti-platelet aggregation, anti-inflammatory, anti-stress and anti-convulsant effects, anti-cancer effects, food poisoning-induced bacterial proliferation inhibitory effects, and immune-enhancing effects have been reported.
마황 (Ephedra sinica Stapf.)은 풍한(風寒)을 소산시키고, 발한해표, 오한발열, 두통, 천식, 해수, 수종, 신체상부 마비, 피부마비, 충혈, 어혈에 효능이 있어 한의학에서 약재로 사용되고 있다.Ephedra ( Ephedra sinica Stapf.) is used as a medicinal in oriental medicine because it is effective in dissipating wind and cold, and is effective in sweating, chills, headache, asthma, seawater, edema, paralysis of the upper body, skin paralysis, hyperemia, and blood clots.
그러나 현재까지, 육계, 백출, 갈근, 백작약 및 마황 복합 추출물의 항비만 효과에 대해서 보고된 바가 없으며, 이에 대한 연구도 전무한 상황이다. However, until now, there has been no report on the anti-obesity effect of the broiler chicken, baekchul, galgeun, ear peony and ephedra complex extract, and there is no research on it.
이에 본 발명자들은 기존 비만 치료를 위해 개발된 약물들의 한계점을 극복하고, 부작용이 적은 새로운 약물을 개발하기 위하여 예의 노력한 결과, 상기 복합 추출물이 신체 에너지 소비 촉진을 통한 비만 억제에 우수한 효과가 있음을 확인함으로써, 본 발명을 완성하였다.Therefore, the present inventors overcame the limitations of existing drugs developed for the treatment of obesity, and as a result of earnest efforts to develop a new drug with fewer side effects, it was confirmed that the complex extract has an excellent effect in suppressing obesity by promoting body energy consumption. Thus, the present invention was completed.
본 발명자들은 육계, 백출, 갈근, 백작약 및 마황 복합 추출물의 인체 에너지대사 촉진 효과에 대해 연구하던 중, 상기 복합 추출물이 PGC1-α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, 과산화소체 증식제-활성화 수용체 감마 보조인자-1 알파) 발현을 증가시키고, AMPK (Adenosine monophosphate-activated protein kinase, 아데노신 일인산-활성화 단백질 키나아제) 인산화를 촉진하는 작용을 통해, 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌다는 것을 확인하여, 본 발명을 완성하였다.While the present inventors were studying the effects of broiler chicken, baekchul, galgeun, white peony, and ephedra complex extracts on promoting human energy metabolism, the complex extracts PGC1-α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, peroxisome proliferator- By increasing the expression of activating receptor gamma cofactor-1 alpha) and promoting AMPK (Adenosine monophosphate-activated protein kinase) phosphorylation, it has anti-obesity effect by promoting body energy consumption. By confirming that, the present invention was completed.
이에, 본 발명의 목적은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 유효성분으로 함유하는, 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 조성물을 제공하는 것이다. Accordingly, it is an object of the present invention to provide a composition containing a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra as active ingredients, having an anti-obesity effect by promoting body energy consumption.
또한, 본 발명의 다른 목적은 육계, 백출, 갈근, 백작약 및 마황의 복합추출물을 유효성분으로 함유하는, 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 건강식품 조성물을 제공하는 것이다.In addition, another object of the present invention is to provide a health food composition containing a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra as active ingredients, which has anti-obesity effect by promoting body energy consumption.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 유효성분으로 함유하는, 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 조성물을 제공한다.In order to achieve the object of the present invention as described above, the present invention provides a composition containing a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra as an active ingredient, having an anti-obesity effect by promoting body energy consumption.
본 발명의 일 구현예로, 상기 복합추출물은 물, C1 내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택되는 1종 이상의 용매로 추출된 것을 특징으로 한다.In one embodiment of the present invention, the complex extract is water, C1 to C4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof. It is characterized in that it is extracted with one or more solvents selected from the group consisting of.
본 발명의 다른 구현예로, 상기 조성물은 과산화소체 증식제-활성화 수용체 감마 보조인자-1 알파 (PGC1-α)의 발현을 증가시키는 것을 특징으로 한다.In another embodiment of the present invention, the composition is characterized in that it increases the expression of peroxisome proliferator-activated receptor gamma cofactor-1 alpha (PGC1-α).
본 발명의 또 다른 구현예로, 상기 조성물은 아데노신 일인산-활성화 단백질 키나아제 (AMPK) 인산화를 촉진시키는 것을 특징으로 한다.In another embodiment of the present invention, the composition is characterized in that it promotes adenosine monophosphate-activated protein kinase (AMPK) phosphorylation.
또한, 본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 유효성분으로 함유하는 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 건강기능성 식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition having an anti-obesity effect through the promotion of body energy consumption containing a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra as active ingredients.
또한, 본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 피험자에게 투여하는 단계를 포함하는 신체 에너지 소비 촉진을 통한 항비만 작용 방법을 제공하고자 한다.In addition, the present invention is to provide a method of anti-obesity action through the promotion of body energy consumption, including the step of administering to the subject a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra.
아울러, 본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물의 신체 에너지 소비 촉진을 통한 항비만 작용 용도를 제공한다.In addition, the present invention provides the use of anti-obesity action through the promotion of body energy consumption of the complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra.
본 발명에 따른 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물은 근육에서 PGC1-α의 발현을 증가시키고, AMPK의 인산화를 촉진시키는 것이 확인되어, 인체 에너지 대사를 촉진함으로써, 에너지 대사의 불균형으로 기인한 비만과 제2형 당뇨병 및 각종 대사성 질환의 치료, 예방, 또는 개선에 활용될 수 있다.It was confirmed that the complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra according to the present invention increases the expression of PGC1-α in muscle and promotes phosphorylation of AMPK, and promotes human energy metabolism, resulting in an imbalance in energy metabolism. It can be utilized for the treatment, prevention, or improvement of obesity, type 2 diabetes, and various metabolic diseases.
도 1은 본 발명의 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 처리한 C2C12 세포에서 PGC1-α의 발현 정도를 각 단일 추출물을 처리한 대조군과 비교하여 확인한 결과를 나타낸 것이다.
도 2는 본 발명의 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 처리한 C2C12 세포에서 AMPK의 인산화 수준을 각 단일 추출물을 처리한 대조군과 비교하여 확인한 결과를 나타낸 것이다.1 shows the results of confirming the expression level of PGC1-α in the C2C12 cells treated with the complex extracts of broiler chicken, baekchul, galgeun, white peony and ephedra of the present invention compared with the control group treated with each single extract.
Figure 2 shows the results of confirming the phosphorylation level of AMPK in the C2C12 cells treated with the complex extract of broiler chicken, baekchul, galgeun, ear pea and ephedra of the present invention compared with the control group treated with each single extract.
본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 유효성분으로 함유하는 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 조성물을 제공한다.The present invention provides a composition having an anti-obesity effect through the promotion of body energy consumption containing a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra as active ingredients.
또한, 본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 유효성분으로 함유하는 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 건강기능성 식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition having an anti-obesity effect through the promotion of body energy consumption containing a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra as active ingredients.
본 발명의 일 실시예에서는 마우스 근육 아세포 (C2C12 myoblasts)를 배양하여 근육세포 (myotubes)로 분화를 유도한 후 실시간 RT-PCR 및 웨스턴 블롯 (western blot) 실험을 각 수행하였다(실시예 1 참조).In one embodiment of the present invention, mouse myoblasts (C2C12 myoblasts) were cultured to induce differentiation into myotubes, and then real-time RT-PCR and western blot experiments were performed (see Example 1). .
본 발명의 다른 실시예에서는 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 제조하였다(실시예 2 참조).In another embodiment of the present invention, a complex extract of broiler chicken, baekchul, galgeun, balsam and ephedra was prepared (see Example 2).
본 발명의 또 다른 실시예에서는 상기 복합 추출물에 의한 과산화소체 증식제-활성화 수용체 감마 보조인자-1 알파 (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PGC1-α)의 발현 정도가 각 단일 추출물을 처리한 대조군과 비교하여 유의적으로 증가하였음을 확인하였다(실시예 3 참조). In another embodiment of the present invention, the expression level of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) by the complex extract is determined by using each single extract. It was confirmed that there was a significant increase compared to the treated control group (see Example 3).
본 발명의 또 다른 실시예에서는 상기 복합 추출물에 의한 아데노신 일인산-활성화 단백질 키나아제 (Adenosine monophosphate-activated protein kinase, AMPK)의 인산화 수준이 각 단일 추출물을 처리한 대조군과 비교하여 유의적으로 증가하였음을 확인하였다(실시예 4 참조).In another embodiment of the present invention, the phosphorylation level of adenosine monophosphate-activated protein kinase (AMPK) by the complex extract was significantly increased compared to the control group treated with each single extract. It was confirmed (see Example 4).
따라서 상기 결과들로 비추어 볼 때, 본 발명에 따른 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물은 근육세포 내 PGC1-α 발현 및 AMPK 인산화 수준을 증가시키는바, 미토콘드리아 기능 장애에 의한 질환, 즉 에너지 대사가 부족하여 유발되는 비만, 당뇨병 등의 대사성 질병이나 노화 관련 질병에 유용한 의약품과, 신체 에너지 소비 촉진을 통한 항비만 효능을 지닌 건강기능식품으로 사용될 수 있다.Therefore, in view of the above results, the complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra according to the present invention increases PGC1-α expression and AMPK phosphorylation level in muscle cells, a disease caused by mitochondrial dysfunction, that is, It can be used as a medicine useful for metabolic diseases such as obesity and diabetes caused by lack of energy metabolism or aging-related diseases, and as a health functional food with anti-obesity effect by promoting body energy consumption.
본 발명의 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물은 당업계에 공지된 통상의 방법, 즉, 통상적인 온도와 압력의 조건하에서, 통상적인 용매를 사용하여 제조될 수 있다. 본 발명의 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물 제조에 사용될 수 있는 추출용매로는 예를 들면, 물, C1 내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매 등의 추출용매를 단독으로 또는 혼합하여 사용 가능하며, 바람직하게는 물이지만, 이에 제한되는 것은 아니다. 상기 추출 용매의 적합한 양은 육계, 백출, 갈근, 백작약 및 마황의 건조 중량의 1 내지 10배 정도이며, 추출방법으로는 열 추출, 냉침 추출, 환류 냉각 추출 및 초음파 추출 등을 사용할 수 있으며, 1회 또는 다수 회 반복하여 추출시켜 사용할 수 있다. 또한, 추출온도는 육계, 백출, 갈근, 백작약 및 마황의 유용성분의 유효활성이 제거되지 않을 정도의 온도이면, 특별히 제한되지 않으나, 바람직하게는 상온에서 침적시켜 추출한다.The complex extract of broiler chicken, baekchul, galgeun, peony and ephedra of the present invention can be prepared by a conventional method known in the art, that is, under normal temperature and pressure conditions, using a conventional solvent. As an extraction solvent that can be used for the preparation of the complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra of the present invention, for example, water, C1 to C4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1 Extraction solvents such as ,3-butylene glycol, methylene chloride, and mixed solvents thereof may be used alone or in combination, and preferably water, but is not limited thereto. A suitable amount of the extraction solvent is about 1 to 10 times the dry weight of broiler chicken, baekchul, brown root, oyster root and ephedra, and heat extraction, cold extraction, reflux cooling extraction, ultrasonic extraction, etc. Alternatively, it can be used by repeatedly extracting multiple times. In addition, the extraction temperature is not particularly limited, as long as the effective activity of the useful ingredients of broiler chicken, baekchul, galgeun, ear pea, and ephedra is not removed, but is preferably extracted by immersion at room temperature.
본 발명의 조성물은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물과 함께 신체 에너지 소비 촉진을 통한 비만 억제 효과를 갖는 공지의 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain one or more known active ingredients having an effect of inhibiting obesity through the promotion of body energy consumption together with a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.As used herein, the term “administration” means providing a given composition of the present invention to a subject by any suitable method.
본 발명의 조성물은, 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로오스 용액, 말토덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당 분야의 적정한 방법으로, 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.The composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration. The pharmaceutically acceptable carrier may be used in a mixture of saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components. , and other conventional additives such as a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets. Furthermore, it can be preferably formulated according to each disease or component by an appropriate method in the art.
본 발명의 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다. 상기 복합 추출물의 일일 투여량은 약 0.0001-500 ㎎/㎏, 바람직하게는 약 0.001-300 ㎎/㎏이며, 하루 일회 내지 수회에 나누어 투여하는 것이 바람직하다.The composition of the present invention may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may vary depending on the patient's weight, age, sex, and health status. , diet, administration time, administration method, excretion rate and the severity of the disease, etc., the range varies. The daily dose of the complex extract is about 0.0001-500 mg/kg, preferably about 0.001-300 mg/kg, and it is preferably administered once or several times a day.
본 발명의 조성물은 신체 에너지 소비 촉진을 통한 비만 억제 효과를 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다. The composition of the present invention may be used alone or in combination with methods using surgery, hormone therapy, drug therapy, and biological response modifiers for the effect of suppressing obesity through promotion of body energy consumption.
본 발명에서, "건강기능식품"이란, 질병의 예방 및 개선, 신체방어, 면역, 병후의 회복, 노화 억제 등 신체조절 기능을 가지는 식품을 말하는 것으로, 장기적으로 복용하였을 때 인체에 무해해야 한다.In the present invention, "health functional food" refers to food having body control functions such as prevention and improvement of diseases, body defense, immunity, recovery from illness, and suppression of aging, and should be harmless to the human body when taken for a long time.
본 발명의 조성물은 신체 에너지 소비 촉진을 통한 비만 억제 효과를 목적으로 건강기능식품에 첨가될 수 있다. 본 발명의 육계, 백출, 갈근, 백작약, 마황의 복합 추출물을 식품 첨가물로 사용할 경우, 상기 육계, 백출, 갈근, 백작약, 마황의 복합 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시 본 발명의 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물은 원료에 대하여 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The composition of the present invention may be added to a health functional food for the purpose of suppressing obesity through the promotion of body energy consumption. When the complex extract of broiler chicken, baekchul, galgeun, oyster root, and ephedra of the present invention is used as a food additive, the complex extract of broiler chicken, baekchul, galgeun, earl yam, and ephedra can be added as it is or used with other foods or food ingredients, It can be used suitably according to a conventional method. The mixed amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In general, in the production of food or beverage, the complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw material. However, in the case of long-term intake for health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.There is no particular limitation on the type of the food. Examples of foods to which the above substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes, and it includes all health functional foods in the ordinary sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당 및 과당과 같은 모노사카라이드, 말토오스 및 수크로오스와 같은 디사카라이드, 덱스트린 및 시클로덱스트린과 같은 폴리사카라이드, 및 자일리톨, 소르비톨 및 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 0.01-0.20g, 바람직하게는 약 0.04-0.10g 이다.The health beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, as in a conventional beverage. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetener, natural sweeteners such as taumatine and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 0.01-0.20 g, preferably about 0.04-0.10 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01-0.20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may contain a carbonation agent used in carbonated beverages, and the like. In addition, the composition of the present invention may contain the pulp for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not critical, but is generally selected in the range of 0.01-0.20 parts by weight per 100 parts by weight of the composition of the present invention.
또한, 본 발명은 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물을 피험자에게 투여하는 단계를 포함하는 신체 에너지 소비 촉진을 통한 비만 억제 방법을 제공한다.In addition, the present invention provides a method of suppressing obesity through the promotion of body energy consumption, comprising administering to the subject a complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra.
상기 피험자는 인간 또는 비-인간을 포함하는 포유류이며, 비-인간 포유류는 마우스, 랫트, 개, 고양이, 말, 소, 양, 염소, 돼지, 토끼 등을 포함하나 이에 한정되지 않는다.The subject is a mammal including a human or a non-human, and the non-human mammal includes, but is not limited to, a mouse, a rat, a dog, a cat, a horse, a cow, a sheep, a goat, a pig, a rabbit, and the like.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are presented to help the understanding of the present invention. However, the following examples are only provided for easier understanding of the present invention, and the content of the present invention is not limited by the examples.
실시예Example 1 : 실험 준비 1: Experiment Preparation
1.1 세포 배양1.1 Cell Culture
마우스 유래 C2C12 세포주는 American Type Culture Collection (ATCC, CRL-1772; Manassas, VA, USA)으로부터 분양받아 사용하였다. 마우스 근육 아세포 (C2C12 myoblasts)를 배양해 근육세포 (myotubes)로 분화를 유도하기 위하여 C2C12 근육세포를 60 mm 페트리 디쉬에 각각 1×106 시딩(seeding)한 후, 10% 소 태아 혈청 (fetal bovine serum, FBS) 및 페니실린 / 스트렙토마이신 1% (penicillin / streptomycin mix 1%)를 함유한 고농도 포도당 Dulbecco’s modified eagle’s medium (DMEM ; Invitrogen, Grand Island, NY, USA)에서 100% 융합 (confluence) 될 때까지 배양하였다. The mouse-derived C2C12 cell line was purchased from the American Type Culture Collection (ATCC, CRL-1772; Manassas, VA, USA). To induce differentiation into myotubes by culturing mouse myoblasts (C2C12 myoblasts), each 1×10 6 seeding of C2C12 myoblasts in a 60 mm Petri dish, 10% fetal bovine serum serum, FBS) and high glucose Dulbecco's modified eagle's medium (DMEM; Invitrogen, Grand Island, NY, USA) containing 1% penicillin / streptomycin (penicillin / streptomycin mix 1%) until 100% confluence. cultured.
분화 유도를 위해, 배지를 분화 배지 (2% 말 혈청이 보충 된 DMEM)로 4일간 24시간 마다 바꾸어 준 후, C2Cl2 근육 세포에 육계, 백출, 갈근, 백작약 및 마황의 복합 추출물 및 각 단일 추출물을 각각 0.5 mg / ml 농도로 동일하게 24 시간 동안 처리하였다.To induce differentiation, the medium was changed to differentiation medium (DMEM supplemented with 2% horse serum) every 24 hours for 4 days. Each was treated with the same concentration of 0.5 mg / ml for 24 hours.
1.2 실시간 1.2 Real-time 역전사중합효소reverse transcriptase 연쇄 반응 (Real Time Reverse Transcriptase-Polymerase Chain Reaction, Real Time RT-PCR) Chain Reaction (Real Time Reverse Transcriptase-Polymerase Chain Reaction, Real Time RT-PCR)
세포를 수거하여 5,000 rpm에서 5분간 원심 분리한 후 TRIzol 시약을 이용하여 총 RNA를 분리하였다. 분리된 RNA에 역전사 중합효소 (reverse transcriptase)를 사용하여 cDNA를 합성하였다. 합성된 cDNA에 SensiFAST SYBR® Lo-ROX mix (Bioline, London, UK) 와 PGC-1α primer (sense; 5'-CAC CAA ACC CAC AGA AAA CAG-3', antisense; 5'-GGG TCA GAG GAA GAG ATA AAG TTG-3') 및 GAPDH primer (sense; 5'-ATT CAA CGG CAC ACT CAA GG-3', antisense; 5'-CAG TGT AGC CCA AGA TGC CCT-3')를 각각 혼합하였다. 이를 변성 (denaturation)을 위해 95 ℃에서 5초, 풀림 (annealing)을 위해 60 ℃에서 10초 및 연장 (extension)을 위해 72 ℃ 에서 20초 조건에서 40 주기로 실시간 연쇄 중합 반응을 수행하였다(Mx300P, Agilent Technologies, CA, USA). Cells were harvested, centrifuged at 5,000 rpm for 5 minutes, and total RNA was isolated using TRIzol reagent. cDNA was synthesized using reverse transcriptase on the isolated RNA. In the synthesized cDNA, SensiFAST SYBR® Lo-ROX mix (Bioline, London, UK) and PGC-1α primer (sense; 5'-CAC CAA ACC CAC AGA AAA CAG-3', antisense; 5'-GGG TCA GAG GAA GAG ATA AAG TTG-3') and GAPDH primer (sense; 5'-ATT CAA CGG CAC ACT CAA GG-3', antisense; 5'-CAG TGT AGC CCA AGA TGC CCT-3') were mixed respectively. This was subjected to real-time chain polymerization in 40 cycles at 95 °C for 5 seconds for denaturation, 10 seconds at 60 °C for annealing, and 20 seconds at 72 °C for extension (Mx300P, Agilent Technologies, CA, USA).
1.3 1.3 웨스턴western 블롯blot (Western blot) (Western blot)
세포를 수거하여 5,000 rpm에서 5분 간 원심분리한 후 PBS 용액으로 2회 세척하고 lysis 용액 (50 mM HEPES, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 ㎍/ml aprotinin)을 이용하여 부유시킨 후 얼음에 30분간 반응시켰다. 20 ㎍의 단백질을 2× sample buffer (100 mM Tris-HCl, pH 6.8, 200 mM dithithreitol, 4% SDS, 0.2% bromophenol blue, 20% glycerol)와 섞어 100 ℃에서 3분 끓인 다음 8∼15% SDS-PAGE를 이용하여 분리하였다. 전기영동을 통해 분리된 겔의 단백질을 니트로섬유소막 (nitrocellulose membrane)으로 4 ℃, 30 V로 16시간 동안 이동(transfer)시켰다. 막 (Membrane)은 10 % 탈지유 (skim milk)로 실온에서 1시간 동안 차단 (blocking)한 다음, 각 단백질의 항체와 상온에서 2시간 반응시켰다. 이를 TBS-T로 3회 세척한 후 anti-pAMPK, AMPK (Cell signaling technology, MA, USA)로 각각 처치한 후, 상온에서 1시간 반응시키고 ECL 용액으로 기질 반응시켜 x-ray film에 감광하였다. X-ray film 상의 밴드는 이미지 (Image-J) 프로그램을 이용하여 AMPK에 대한 pAMPK의 발현 비율로 표시하였다.The cells were harvested, centrifuged at 5,000 rpm for 5 minutes, washed twice with PBS solution, and lysis solution (50 mM HEPES, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 μg/ ml aprotinin) and then reacted on ice for 30 minutes. 20 μg of protein is mixed with 2× sample buffer (100 mM Tris-HCl, pH 6.8, 200 mM dithithreitol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and boiled at 100 ° C for 3 minutes, then 8-15% SDS -PAGE was used to separate. The protein in the gel separated through electrophoresis was transferred to a nitrocellulose membrane at 4° C. and 30 V for 16 hours. The membrane was blocked with 10% skim milk at room temperature for 1 hour, and then reacted with the antibody of each protein for 2 hours at room temperature. This was washed 3 times with TBS-T, treated with anti-pAMPK and AMPK (Cell signaling technology, MA, USA), respectively, and reacted at room temperature for 1 hour, followed by substrate reaction with ECL solution, and photosensitized to x-ray film. The band on the X-ray film was expressed as the expression ratio of pAMPK to AMPK using the Image-J program.
실시예 2 : 육계, 백출, 갈근, 백작약 및 마황 (Example 2: Broiler chicken, baekchul, galgeun, earl yam and ephedra ( Cinnamomum cassia Cinnamomum cassia Blume, Blume, Atractylodes macrocephalaAtractylodes macrocephala Koidzumi, Koidzumi, Pueraria lobata Pueraria lobata (Willd.) Ohwi, (Willd.) Ohwi, Paeonia lactifloraPaeonia lactiflora Pallas and Pallas and Ephedra sinicaEphedra sinica Stapf.) 복합 추출물의 제조 Stepf.) Preparation of complex extracts
건조된 육계, 백출, 갈근, 백작약 및 마황 각 50 g 을 준비한 후, 정제수 2.5 L 를 가하고 열탕 추출기에서 3시간 동안 가열하여 복합 성분의 물 추출물을 얻었다. 이를 여과지(Whatman NO. 1; Sigma-Aldrich, St. Louis, MO, USA)로 여과한 후 회전식 감압농축기로 감압 농축하여 상기 복합 추출물의 건조 파우더를 제조하였으며, 수득율은 26.9% 이었다. 또한 비교 실험을 위해, 육계, 백출, 갈근, 백작약 및 마황의 각 단일 추출물을 제조하고자, 해당 건조물을 각 200 g 씩 준비해 정제수 2 L 를 가하고 각각 열탕 추출기에서 3시간 동안 가열한 후 상기 방법과 동일한 방법을 사용하여 각 단일 추출물의 건조 파우더를 제조하였다. 수득율은 각각 육계 6.7%, 백출 26.0%, 갈근 32.0%, 백작약 40.9% 및 마황 6% 이었다.After preparing 50 g of each dried broiler chicken, baekchul, brown root, white peony and ephedra, 2.5 L of purified water was added and heated in a hot water extractor for 3 hours to obtain a water extract of the complex component. This was filtered through filter paper (Whatman NO. 1; Sigma-Aldrich, St. Louis, MO, USA) and concentrated under reduced pressure using a rotary vacuum concentrator to prepare dry powder of the composite extract, and the yield was 26.9%. In addition, for the comparative experiment, to prepare each single extract of broiler chicken, baekchul, galgeun, white peony, and ephedra, prepare 200 g each of the dried product, add 2 L of purified water, and heat each in a boiling water extractor for 3 hours. The method was used to prepare a dry powder of each single extract. The yields were 6.7% for broiler chicken, 26.0% for baekchul, 32.0% for galgeun, 40.9% for earl, and 6% for ephedra, respectively.
실시예Example 3 : 육계3: Broiler , 백출, , White, 갈근craving , 백작약 및 마황의 복합 추출물에 의한 , by the complex extract of earl and ephedra PGCPGC -- 1One α의 발현 변화 확인Confirmation of expression change of α
PGC-1α는 세포내에서 에너지 대사를 조절하는 핵심 인자로 미토콘드리아의 신생에 있어서 중요한 요소이며, 골격근에서 지방산 산화 및 열 발생에 중요한 역할을 담당한다. 이에 C2C12 세포에서 육계, 백출, 갈근, 백작약 및 마황의 복합추출물에 의한 PGC-1α의 발현을 확인하기 위하여 상기 실시예 1-2의 실시간 RT-PCR 방법으로 PGC-1α의 mRNA 발현량을 측정하였다. PGC-1α is a key factor regulating energy metabolism in cells, and is an important factor in mitochondrial angiogenesis, and plays an important role in fatty acid oxidation and thermogenesis in skeletal muscle. Therefore, in order to confirm the expression of PGC-1α by the complex extract of broiler chicken, baekchul, galgeun, oyster root and ephedra in C2C12 cells, the mRNA expression level of PGC-1α was measured by the real-time RT-PCR method of Example 1-2. .
그 결과, 도 1에 나타낸 바와 같이, 각 단일 추출물에 비하여 육계, 백출, 갈근, 백작약 및 마황 복합 추출물의 처치 시에 PGC-1α의 발현량이 현저하게 증가한 것을 확인하였다.As a result, as shown in FIG. 1 , it was confirmed that the expression level of PGC-1α was significantly increased during treatment of the broiler chicken, baekchul, galgeun, ear pea, and ephedra complex extract compared to each single extract.
실시예Example 4 : 육계4: Broiler , 백출, , White, 갈근craving , 백작약 및 마황의 복합 추출물에 의한 , by the complex extract of earl and ephedra AMPKAMPK 의 인산화 변화 확인Confirmation of phosphorylation changes in
AMPK는 세포 내의 에너지 항상성 유지에 센서 역할을 하는 주요 효소로 인산화를 통해 골격근에서의 미토콘드리아 신생, 글루코오스 수송, 및 지방산 산화를 증가시킨다. 또한, 인산화 된 AMPK는 PGC-1α 활성을 직접적으로 증가시키는 직접적으로 작용을 한다. 이에 AMPK, pAMPK의 단백질 발현량을 상기 실시예 1-3의 웨스턴 블롯 (Western blot) 방법으로 측정하였다. AMPK is a major enzyme that acts as a sensor in the maintenance of energy homeostasis in cells and increases mitochondrial neoplasia, glucose transport, and fatty acid oxidation in skeletal muscle through phosphorylation. In addition, phosphorylated AMPK acts directly to directly increase PGC-1α activity. Accordingly, the protein expression levels of AMPK and pAMPK were measured by the Western blot method of Examples 1-3.
그 결과, 도 2에 나타낸 바와 같이, 각 단일 추출물에 비하여 육계, 백출, 갈근, 백작약 및 마황 복합 추출물 처치 시에 AMPK의 인산화가 현저하게 증가한 것을 확인하였다.As a result, as shown in Figure 2, compared to each single extract, it was confirmed that phosphorylation of AMPK was significantly increased when treated with broiler chicken, baekchul, galgeun, oyster root and ephedra complex extract.
상기 내용을 종합한 결과, 본 발명의 육계, 백출, 갈근, 백작약 및 마황 복합 추출물이 근육세포 내 PGC-1α의 발현량 및 AMPK의 인산화를 유의적으로 증가시킨다는 것을 확인할 수 있었는바, 상기 복합 추출물이 신체 에너지 소비 촉진을 통한 항비만 작용에 우수한 효과를 가지고 있음을 알 수 있다.As a result of synthesizing the above, it was confirmed that the complex extract of broiler chicken, baekchul, galgeun, ear pea and ephedra of the present invention significantly increased the expression level of PGC-1α and phosphorylation of AMPK in muscle cells, the complex extract It can be seen that this body has an excellent effect on anti-obesity through the promotion of energy consumption.
이하 본 발명의 조성물을 위한 제제예를 설명하나, 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples for the composition of the present invention will be described, but the present invention is not intended to be limited, but only specifically described.
제제예Formulation example 1 : 약학적 제제의 제조 1: Preparation of pharmaceutical formulations
1. 산제의 제조1. Preparation of powder
육계, 백출, 갈근, 백작약 및 마황의 복합 추출물 200㎎200mg of complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra
유당 100㎎Lactose 100mg
상기의 성분을 혼합하고 기밀포에 충진 하여 산제를 제조하였다.The above ingredients were mixed and filled in an airtight cloth to prepare a powder.
2. 정제의 제조2. Preparation of tablets
육계, 백출, 갈근, 백작약 및 마황의 복합 추출물 200㎎200mg of complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra
옥수수전분 100㎎Corn Starch 100mg
유당 100㎎Lactose 100mg
스테아르산 마그네슘 2㎎Magnesium stearate 2mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above ingredients, tablets were prepared by tableting according to a conventional method for manufacturing tablets.
3. 캡슐제의 제조3. Preparation of capsules
육계, 백출, 갈근, 백작약 및 마황의 복합 추출물 200㎎200mg of complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra
옥수수전분 100㎎Corn Starch 100mg
유당 100㎎Lactose 100mg
스테아르산 마그네슘 2㎎Magnesium stearate 2mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above ingredients, the capsules were prepared by filling in gelatin capsules according to a conventional manufacturing method of capsules.
4. 주사제의 제조4. Preparation of injections
육계, 백출, 갈근, 백작약 및 마황의 복합 추출물 200㎎200mg of complex extract of broiler chicken, baekchul, galgeun, earl yam and ephedra
만니톨 100㎎Mannitol 100mg
Na2HPO4·12H2O 2㎎Na 2 HPO 4 12H 2 O 2mg
주사용 멸균 증류수 적량Appropriate amount of sterile distilled water for injection
통상의 주사제의 제조방법에 따라 1 앰플당 (2㎖) 상기의 성분을 혼합하여 주사제를 제조하였다.An injection was prepared by mixing the above ingredients per ampoule (2 ml) according to a conventional injection preparation method.
제제예Formulation example 2 : 식품의 제조 2: Manufacture of food
본 발명의 복합 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the complex extract of the present invention were prepared as follows.
1. 조리용 양념의 제조1. Preparation of cooking seasoning
복합 추출물 20-95 중량%로 건강 증진용 조리용 양념을 제조하였다.A cooking seasoning for health promotion was prepared with 20-95% by weight of the complex extract.
2. 토마토 케찹 및 소스의 제조2. Preparation of Tomato Ketchup and Sauce
복합 추출물 0.2-1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.0.2-1.0 wt% of the complex extract was added to tomato ketchup or sauce to prepare tomato ketchup or sauce for health promotion.
3. 밀가루 식품의 제조3. Manufacture of wheat flour food
복합 추출물 0.5-5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.5-5.0 wt% of the complex extract was added to wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers, and noodles to prepare health-promoting foods.
4. 스프 및 육즙(gravies)의 제조4. Preparation of soups and gravies
복합 추출물 0.1-5.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1-5.0 wt% of the complex extract was added to the soup and broth to prepare health-promoting meat products, noodle soups and broths.
5. 그라운드 비프(ground beef)의 제조5. Preparation of ground beef
복합 추출물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10 wt% of the complex extract was added to ground beef to prepare ground beef for health promotion.
6. 유제품(dairy products)의 제조6. Manufacture of dairy products
복합 추출물 5-10 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5-10% by weight of the complex extract was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
제제예Formulation example 3 : 음료의 제조 3: Preparation of beverages
1. 탄산음료의 제조1. Manufacture of carbonated beverages
복합 추출물 10-15%, 설탕 5-10%, 구연산 0.05-0.3%, 카라멜 0.005-0.02%, 비타민 C 0.1-1%의 첨가물을 혼합하고, 여기에 75-80%의 정제수를 섞어서 시럽을 만들었다. 상기 시럽을 85-98℃에서 20-180초간 살균하여 냉각수와 1:4의 비율로 혼합한 다음 탄산가스를 0.5-0.82%를 주입하여 복합 추출물을 함유하는 탄산음료를 제조하였다.Complex extract 10-15%, sugar 5-10%, citric acid 0.05-0.3%, caramel 0.005-0.02%, vitamin C 0.1-1% additives were mixed, and 75-80% purified water was mixed to make syrup. . The syrup was sterilized at 85-98° C. for 20-180 seconds, mixed with cooling water in a ratio of 1:4, and then 0.5-0.82% of carbon dioxide was injected to prepare a carbonated beverage containing the complex extract.
2. 건강음료의 제조2. Manufacture of health drinks
복합 추출물(고형분 2.5%, 97.16%), 대추 엑기스(65 brix, 2.67%), 과체복합 추출물(고형분 70%, 0.12%), 비타민 C(0.02%), 판톤텐산칼슘 (0.02%), 감초 추출물(고형분 65%, 0.01%)을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Complex extract (solid content 2.5%, 97.16%), jujube extract (65 brix, 2.67%), fruit complex extract (solid content 70%, 0.12%), vitamin C (0.02%), calcium pantonethenate (0.02%), licorice extract (65% solid content, 0.01%) was homogeneously mixed and instantaneously sterilized, and then packaged in small packaging containers such as glass bottles and plastic bottles to prepare health drinks.
3. 야채쥬스의 제조3. Preparation of vegetable juice
복합 추출물 0.5g을 토마토 또는 당근 쥬스 1,000㎖에 가하여 건강 증진용 야채쥬스를 제조하였다.By adding 0.5 g of the complex extract to 1,000 ml of tomato or carrot juice, vegetable juice for health promotion was prepared.
4. 과일쥬스의 제조4. Preparation of fruit juice
복합 추출물 0.1g을 사과 또는 포도 쥬스 1,000㎖에 가하여 건강 증진용 과일쥬스를 제조하였다.By adding 0.1 g of the complex extract to 1,000 ml of apple or grape juice, fruit juice for health promotion was prepared.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술 분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.
Claims (6)
An anti-obesity pharmaceutical composition containing a complex extract of a mixture consisting of broiler chicken, baekchul, galgeun, ear pea and ephedra as an active ingredient.
상기 복합 추출물은 물, C1 내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택되는 1종 이상의 용매로 추출된 것을 특징으로 하는, 항비만 약학적 조성물.
According to claim 1,
The complex extract is at least one selected from the group consisting of water, C1 to C4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof. An anti-obesity pharmaceutical composition, characterized in that extracted with a solvent.
상기 조성물은 과산화소체 증식제-활성화 수용체 감마 보조인자-1 알파 (peroxisome proliferator-activated receptor gamma coactivator-1 alpha, PGC-1α)의 발현을 증가시키는 것을 특징으로 하는, 항비만 약학적 조성물.
According to claim 1,
The composition is a peroxisome proliferator-activated receptor gamma coactivator-1 alpha (peroxisome proliferator-activated receptor gamma coactivator-1 alpha, PGC-1α) characterized in that to increase the expression, anti-obesity pharmaceutical composition.
상기 조성물은 아데노신 일인산-활성화 단백질 키나아제 (Adenosine monophosphate-activated protein kinase, AMPK)의 인산화를 촉진시키는 것을 특징으로 하는, 항비만 약학적 조성물.
According to claim 1,
The composition is adenosine monophosphate-activated protein kinase (Adenosine monophosphate-activated protein kinase, AMPK) characterized in that to promote phosphorylation, anti-obesity pharmaceutical composition.
An anti-obesity health functional food composition containing, as an active ingredient, a complex extract of a mixture consisting of broiler chicken, baekchul, galgeun, ear pea, and ephedra.
상기 복합추출물은 물, C1 내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택되는 1종 이상의 용매로 추출된 것을 특징으로 하는, 항비만 건강기능성 식품 조성물.6. The method of claim 5,
The complex extract is at least one selected from the group consisting of water, C1 to C4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof. An anti-obesity health functional food composition, characterized in that it is extracted with a solvent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160176561A KR102449530B1 (en) | 2016-12-22 | 2016-12-22 | Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160176561A KR102449530B1 (en) | 2016-12-22 | 2016-12-22 | Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180073095A KR20180073095A (en) | 2018-07-02 |
KR102449530B1 true KR102449530B1 (en) | 2022-10-04 |
Family
ID=62914076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160176561A KR102449530B1 (en) | 2016-12-22 | 2016-12-22 | Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102449530B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102388367B1 (en) * | 2020-02-24 | 2022-04-18 | 부산대학교 산학협력단 | Health functional foods compositions comprising Sanguisorba officinalis L extract |
KR102594107B1 (en) * | 2020-08-28 | 2023-10-27 | 한국과학기술연구원 | Composition for antifatique or exercise performance comprising mixed extract of Atractylodes macrocephala and Agastache rugosa |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080050794A (en) * | 2006-12-04 | 2008-06-10 | 장용훈 | Composition comprising complex crude drug extract (mst) for preventing and treating obesity |
KR20110087808A (en) * | 2010-01-27 | 2011-08-03 | 이경준 | Prevention of the obesity which contains the complex herb medicine extract (mdt), development of the therapeutic material and the composition development which treats constitutional by liver functional improvements and triglyceride decreases simultaneously |
KR101691205B1 (en) * | 2014-03-07 | 2016-12-30 | 동의대학교 산학협력단 | Composition comprising herbal extract for preventing or treating fatty liver disease |
-
2016
- 2016-12-22 KR KR1020160176561A patent/KR102449530B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20180073095A (en) | 2018-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101785495B1 (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
KR102449530B1 (en) | Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. | |
KR20160123130A (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
KR102087033B1 (en) | Compositions for reducing weight comprising Oenothera extract or its fraction as effective component | |
KR101891879B1 (en) | Composition for improving metabolism containing extraction of Atractylodes macrocephala Koidzumi | |
KR100805865B1 (en) | Anti-thrombus agent comprising extract of herbal mixture | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR20110051543A (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
KR100902368B1 (en) | Pharmaceutical composition for the prevention and treatment of impotency containing extract of gastrodia elata | |
KR20050014615A (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
KR101109771B1 (en) | Composition for prevention or treatment of heart diseases comprising extract of yuzu | |
KR20160094313A (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
KR101828155B1 (en) | Composition for improving Myogenesis containing extraction of Atractylodes macrocephala Koidzumi | |
KR20210003523A (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising Lycium chinense extract as effective component | |
KR101325825B1 (en) | Composition comprising oenanthe javanica organic acid extract for anti-inflammation | |
KR102632034B1 (en) | Composition for preventing, ameliorating or treating arthritis and joint pain comprising mixed extract of Alpiniae Oxyphyllae, Paeonia lactiflora and Glycyrrhiza uralensis as effective component | |
KR102541649B1 (en) | A composition for improving, preventing and treating of woman menopause related disease | |
KR20100108869A (en) | Composition containing extract of herbal mixture for prevention or treatment of diabetes | |
KR102185006B1 (en) | A composition for improving, preventing and treating of asthma and vascular disease | |
KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
KR20240029006A (en) | Food Composition For Improving Skin Elasticity Or Moisture | |
KR20230068291A (en) | Composition for muscle strengthening, muscle development or for preventing, ameliorating or treating sarcopenia comprising Perilla frutescens leaf extract as effective component | |
KR20230161339A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Ribes fasciculatum var. chinense extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |